JBIO
Jade Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.90
+0.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 18.0K | — | 282.0K | 96.0K | 68.0K |
| Gross Profit | (18.0K) | — | (282.0K) | (96.0K) | (68.0K) |
| Operating Expenses | |||||
| R&D Expense | 136.7M | 93.1M | 53.2M | 64.2M | 38.6M |
| SG&A Expense | 28.1M | 20.4M | 21.1M | 17.1M | 14.5M |
| General & Admin Expense | 11.7M | 20.2M | — | — | — |
| Selling & Marketing Expense | 100.0K | 200.0K | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 164.7M | 113.5M | 74.3M | 81.3M | 53.2M |
| Cost and Expenses | 164.7M | 113.5M | 74.6M | 81.4M | 53.2M |
| Operating Income (EBIT) | (164.7M) | (113.5M) | (74.6M) | (81.4M) | (53.2M) |
| Non-Operating | |||||
| Interest Income | 11.7M | 7.8M | 5.0M | 5.9M | 1.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 11.7M | 7.8M | 5.0M | 5.9M | 1.8M |
| Other Non-Op Income/Expense | 11.6M | (13.8M) | 5.0M | 5.9M | 1.8M |
| Non-Operating Income (excl Interest) | (8.4M) | 13.8M | (5.0M) | (5.9M) | (1.8M) |
| EBT (Pre-Tax Income) | (153.2M) | (127.4M) | (69.6M) | (75.5M) | (51.5M) |
| Income Tax Expense | 89.0K | 58.0K | 55.0K | 56.0K | 25.0K |
| Bottom Line | |||||
| Net Income | (153.2M) | (127.4M) | (69.6M) | (75.5M) | (51.5M) |
| Earnings from Cont. Ops | (153.2M) | (127.4M) | (69.6M) | (75.5M) | (51.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (143.7M) | (127.4M) | (69.6M) | (75.5M) | (51.5M) |
| Per Share | |||||
| Basic EPS | ($2.75) | ($4.06) | ($85.26) | ($100.38) | ($73.67) |
| Diluted EPS | ($2.75) | ($4.06) | ($85.26) | ($100.38) | ($73.67) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 61.1M | 31.4M | 816634 | 752332 | 699202 |
| Diluted Shares Outstanding | 61.1M | 31.4M | 816634 | 752332 | 699202 |
| Profitability Metrics | |||||
| EBITDA | (156.3M) | (127.3M) | (69.3M) | (75.4M) | (51.4M) |
| D&A | 39.0K | 26.0K | 282.0K | 96.0K | 68.0K |
| EBIT | (156.3M) | (127.4M) | (69.6M) | (75.5M) | (51.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026